Notice of Intent to Publish a Funding Opportunity Announcement for Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21)

0
290

Opportunity ID: 293628
Opportunity Number: NOT-AR-18-007
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement for Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.846
Eligible Applicants: State governments
County governments
City or township governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: May 05, 2017
Last Updated Date: May 05, 2017
Estimated Synopsis Post Date: Jun 02, 2017
Fiscal Year: 2018
Award Ceiling: $400,000
Award Floor:
Estimated Total Program Funding: $0
Expected Number of Awards: 0
Description: ?This Notice serves to alert the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to reissue PAR-14-192, ‘Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21),’ to solicit applications for short-term clinical trials.   The goal of the NIAMS clinical trial program is to prevent or reduce symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal or skin diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster short-term interventional studies in humans that will ultimately lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these diseases. The NIAMS has updated the requirements for clinical trials that are allowable through the R21 mechanism, which may impact applications submitted in response to this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.    The FOA is expected to be published in Summer 2017 with an expected application due date in Fall 2017.  This FOA will utilize the R21 activity code.
Version: Forecast 1





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here